Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Drug development

Topic: Risk, prevention and care in population studies

Plain-language summary

Background Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), particularly semaglutide, have demonstrated substantial efficacy for glycemic control and weight management and are increasingly prescribed across diverse populations. Rapid expansion of indications, formulations, and real-world use has outpaced comprehensive evaluation of long-term safety, tolerability, and adherence, raising important concerns for clinical practice. Objective This narrative review aims to synthesize current evidence on the efficacy and safety profile of semaglutide, with a focus on adverse events, treatment persistence, perioperative considerations, and use in special populations, to support clinical decision-making and pharmacist-led patient care.

What this study adds

Evidence grade: High

This is a narrative review. This narrative review synthesizes current evidence on the efficacy and safety of semaglutide for obesity management, focusing on adverse events, treatment persistence, perioperative considerations and special populations. It does not address Alzheimer's disease treatment, cure or prevention.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Hajibandeh, S., Tao, Y. A., Hsieh, M. H., Liu, H. G., Cheng, Y. F., Lee, K. H., et al. (2026). Semaglutide for obesity management: A narrative review of efficacy, safety, and future directions. Journal of the American Pharmacists Association : JAPhA. https://doi.org/10.1016/j.japh.2026.103117

Vancouver

Hajibandeh S, Tao YA, Hsieh MH, Liu HG, Cheng YF, Lee KH, et al. Semaglutide for obesity management: A narrative review of efficacy, safety, and future directions. Journal of the American Pharmacists Association : JAPhA. 2026. doi:10.1016/j.japh.2026.103117. PMID: 42025961.

BibTeX

@article{hajibandeh2026-42025961,
  author  = {Hajibandeh, S. and Tao, Y. A. and Hsieh, M. H. and Liu, H. G. and Cheng, Y. F. and Lee, K. H. and Hsieh, S. Y. and Lu, C. H.},
  title   = {{Semaglutide for obesity management: A narrative review of efficacy, safety, and future directions}},
  journal = {Journal of the American Pharmacists Association : JAPhA},
  year    = {2026},
  doi     = {10.1016/j.japh.2026.103117},
  pmid    = {42025961},
  url     = {https://doi.org/10.1016/j.japh.2026.103117}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Why it matters

This narrative review synthesizes current evidence on the efficacy and safety of semaglutide for obesity management, focusing on adverse events, treatment persistence, perioperative considerations and special populations. It does not address Alzheimer's disease treatment, cure or prevention.

Study details

How this study scored 35/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 0 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 5 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 0 of 7; Citations per year 0 of 5; Impact for its field and year 0 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 1 of 4; Institution's track record 2 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 35 of 100.35 of 100 points earned65 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Journal of the American Pharmacists Association : JAPhA)
Journal's citation record 1 / 4 Journal of the American Pharmacists Association: journal h-index 82 (OpenAlex, 2026-10-29)
Study design 0 / 12 Design recorded as “narrative review”, which our rubric does not rank (not stated in the record — scored 0)
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 0 / 7 Cited 0 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.0 citations a year over 2 year(s) since 2026
Impact for its field and year 0 / 6 Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 1 / 4 Last-listed author Chi‐Hua Lu: h-index 10 (OpenAlex, whole career)
Institution's track record 2 / 3 Columbia University: institution h-index 1,824 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 7 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 42025961)
Free to read 0 / 2 Behind a paywall — scores zero
Total 35 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Drug development from nearby years

Also in Drug development

104 studies in the library are filed under Drug development with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Drug development hub.

Similar studies

More on Drug development

See all studies in Drug development →